Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). Diabetes can be categorized into three primary forms - type 1, type 2, and gestational diabetes - each with distinct underlying causes. With the prevalence of diabetes increasing at an alarming rate, there is a critical need for innovative research solutions to better understand and combat this epidemic. The use of mouse models enables the study of diabetes in a way that closely mirrors the disease in humans, helping to explore disease mechanisms, find biomarkers, and evaluate potential treatments.

Ace Therapeutics provides diverse diabetic mouse models targeting type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). The T1DM mouse models allow researchers to study the mechanism of type 1 diabetes, identify biomarkers, and test potential therapies. Mouse models for T2DM study is generated by feeding mice a high-fat or high-sugar diet or genetically modifying mice to develop obesity and insulin resistance. These models matter a lot in type 2 diabetes research. Different from T2DM mouse models, GDM mouse models involve feeding mice a high-fat or high-sugar diet during pregnancy or genetically modifying mice to develop impaired glucose tolerance and insulin resistance during pregnancy.

“With the launch of our diabetic mouse models, we are excited to provide researchers with a reliable and versatile platform to advance their understanding of diabetes and develop novel treatments,” said the marketing manager of Ace Therapeutics. “Our models offer a high level of accuracy and reproducibility, allowing for more precise and reliable results in preclinical studies.”

Ace Therapeutics’ mouse models mimic the key characteristics of human diabetes, such as hyperglycemia, insulin resistance, and pancreatic dysfunction, making them invaluable for investigating disease pathology and testing new therapeutics. These mouse models are available for purchase immediately and can be customized to meet specific research needs as well. 

Ace Therapeutics, a contract research organization (CRO) based in the United States, is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease.

Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high intraocular pressure. Gene therapy for glaucoma is a promising field of research focused on developing treatments to address the underlying causes of the disease, potentially offering more effective and long-lasting solutions than current options. For example, utilizing CRISPR/Cas9 and other genome-editing tools, scientists are exploring ways to correct mutations that lead to glaucoma. This method could provide a more permanent solution by addressing the root genetic causes of the disease. As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials.

As an innovative ophthalmic disease research company with a wide range of services in basic research, drug development, and preclinical studies, Ace Therapeutics has expanded its portfolio to include gene therapy solutions designed specifically to accelerate glaucoma drug discovery and development. “Our mission at Ace Therapeutics has always been to push the boundaries of science to deliver life-changing therapies,” said the business development manager of Ace Therapeutics. “With the launch of our gene therapy development services, we are forging new pathways in glaucoma research, harnessing cutting-edge technologies to unlock potential cures that were once thought beyond reach.”

Ace Therapeutics’ gene therapy development services for glaucoma offer comprehensive solutions that include stem cell-based gene therapy development, siRNA development, gene delivery system engineering, and preclinical testing. Based on years of CRO experience, Ace Therapeutics' integrated development pipeline ensures a seamless end-to-end process, from initial discovery through to preclinical validation, designed to streamline the development timeline and enhance success rates.

Ace Therapeutics is a pioneer in ophthalmic diseases, dedicated to providing supportive research services to advance scientific study and improve research outcomes. With the commitment to bridge the gap between scientific discoveries and clinical applications, Ace Therapeutics has established strategic partnerships with academic institutions and biotech firms to foster collaboration and innovation.